AcuraBio partners with Cytiva to alleviate supply constraints for mRNA, cell and gene therapies

Latest News

AcuraBio has announced that it will provide a cGMP plasmid DNA contract development and manufacturing service using Cytiva’s new process platform technology.

AcuraBio said it expects to produce more plasmid DNA for its customers around the world using Cytiva’s latest bacterial plasmid two-step purification protocol.

The new protocol features single-use purification technology which delivers efficiency, high purity level outcome and sustainable process.

AcuraBio CEO Guillaume Herry said, “We are very excited to implement Cytiva’s latest technology especially because the access and production of plasmid DNA has been a bottleneck in the advanced therapy market. We intend to bring biotechs and biopharma companies a more high-quality plasmid DNA quicker than before to help the development of new therapies such as viral vectors and mRNA.”

According to Jon Ince, the general manager of commercial for Cytiva in Australia and New Zealand, “The adoption of Cytiva’s FlexFactory configurable manufacturing train, within AcuraBio’s assets will enable AcuraBio to advance and better serve their customers based with efficient and flexible cGMP manufacturing services that address the increasing demand for high-quality therapeutics within the Australia and New Zealand region and beyond.”